DEFA14A: Amgen Highlights Strong 2024 Performance and Outlines Board Recommendations for 2025 Annual Meeting

Amgen reports record sales for multiple products, advancements in its research and development pipeline, and outlines key board recommendations for the upcoming annual meeting.

Summary

• Amgen had a strong year in 2024, achieving record annual sales for 21 products.
• The company made progress in its research and development programs across General Medicine, Rare Disease, Oncology, and Inflammation.
• Key developments include the initiation of Phase 3 clinical trials for MariTide in chronic weight management and the launch of IMDELLTRA in the U.S. for extensive-stage small cell lung cancer.
• Amgen invested $6.0 billion in research and development and $1.1 billion in capital expenditures.
• The company reduced its debt by $4.5 billion and returned $5.0 billion to stockholders, including $4.8 billion in dividends.
• The Board of Directors recommends voting FOR the election of director nominees, the advisory vote to approve executive compensation, and the ratification of Ernst & Young LLP as independent registered public accountants.
• Amgen's Board consists of highly qualified leaders, with eight new directors appointed since 2016.
• The company emphasizes corporate governance best practices, including a highly independent board and stockholder engagement.
• Executive compensation is aligned with business strategy and is performance-based.
• The 2025 Annual Meeting of Stockholders will be held virtually on May 23, 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial performance, R&D progress, and shareholder returns. The tone is optimistic and confident, reflecting well on the company's prospects.

Positives

• Amgen achieved record annual sales for a significant number of products.
• The company's R&D pipeline is progressing with multiple products entering or advancing in clinical trials.
• Several products received regulatory approvals and designations, expanding their market reach and potential.
• Amgen is investing in manufacturing excellence to meet future demand.
• The company is committed to patient assistance programs and science education.
• Amgen is reducing debt and returning capital to stockholders.
• The Board of Directors is highly qualified and committed to corporate governance best practices.
• Executive compensation is aligned with performance.

Future Outlook

Amgen is focused on long-term growth, continuing to invest in research and development, expanding manufacturing capacity, and returning capital to stockholders.

Management Comments

• 2024 was another year of strong execution as we delivered record annual sales for twenty-one of our products and an ambitious research and development program agenda across our four therapeutic areas (General Medicine, Rare Disease, Oncology, and Inflammation).
• We accomplished these objectives while maintaining a disciplined approach to capital allocation, investing in long-term growth and reducing our debt and returning capital to our stockholders.
• We would welcome the opportunity to discuss any of our proxy statement voting matters with you.

Industry Context

Amgen's focus on innovation and strategic acquisitions, such as Horizon Therapeutics, reflects a broader trend in the pharmaceutical industry to expand product portfolios and address unmet medical needs. The company's advancements in oncology and rare diseases align with growing investment and research in these areas.

Comparison to Industry Standards

• Amgen's R&D investment of $6.0 billion is substantial, placing it among the top pharmaceutical companies in terms of research spending; for example, companies like Roche and Novartis also invest heavily in R&D.
• The company's debt reduction of $4.5 billion demonstrates a commitment to financial stability, which is a key metric for investors when comparing Amgen to peers like AbbVie and Pfizer.
• Amgen's return of capital to stockholders through dividends is a common practice among established pharmaceutical companies, but the specific amount and yield can be compared to companies like Johnson & Johnson to assess its attractiveness to investors.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance and return of capital.
• Patients will have access to new and innovative therapies.
• Employees will benefit from the company's investment in manufacturing and job creation.
• Communities will benefit from the company's philanthropic efforts and science education programs.

Next Steps

• Stockholders are encouraged to vote on the Board's recommendations for the Annual Meeting.
• The company will continue to advance its research and development programs.
• Amgen will continue to invest in manufacturing capacity and patient assistance programs.

Key Dates

Keywords

Amgen, Annual Meeting, Stockholders, Board of Directors, Executive Compensation, Research and Development, Pharmaceuticals, Healthcare, Corporate Governance, Clinical Trials, Drug Approvals, Financial Performance